Lupin unveils generic contraceptive drug in US

Mumbai: Global pharma major Lupin Limited has announced the launch of Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP, 0.3 mg/0.03 mg, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP, 0.3 mg/0.03 mg is the generic equivalent of Lo/Ovral-28 (Norgestrel and Ethinyl Estradiol) Tablets, 0.3 mg/0.03 mg of Wyeth Pharmaceuticals LLC and is a contraceptive drug indicated to prevent pregnancy.

Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of USD 33 million in the U.S. (IQVIA MAT October 2023).

Read also: Lupin type 2 diabetes drug Canagliflozin bags USFDA tentative approval

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers.

Read also: USFDA approves Lupin Bromfenac Ophthalmic Solution